A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Trial details
- Registry ID
- NCT06774131
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as UGN-104 (mitomycin) for pyelocalyceal solution
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerNCT06774131 | URGN | Phase 3 | Recruiting | 2027-03Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |